Digitalis for treatment of congestive heart failure in patients in sinus rhythm.

Machine translation Machine translation
此檔案並非最近版本

觀看最近期版本

类别 Systematic review
期刊Cochrane Database of Systematic Reviews
Year 2001
背景:应用巴利昔单抗诱导疗法在肝移植中的益处尚不清楚。目前的荟萃分析是评估巴利昔单抗在肝移植中的利与弊。数据来源:我们从1998年7月至2015年12月在以下数据库中搜索了英文的相关出版物:MEDLINE,PubMed,Ovid,EMBASE,Web of Science和Cochrane图书馆。结果:巴利昔单抗显着降低肝移植后新生糖尿病的发生率(RR = 0.56; 95%CI:0.34-0.91; P = 0.02)。亚组分析显示,巴利昔单抗联合无类固醇免疫抑制剂显着降低了活检证实的急性排斥反应发生率(RR = 0.62; 95%CI:0.39-0.97; P = 0.04)和新发高血压(RR = 0.62; 95 %CI:0.42-0.93; P = 0.02)。结论:巴利昔单抗可有效减少新生糖尿病。此外,basiliximab与无类固醇免疫抑制剂组合显示统计学益处,可减少活检证实的急性排斥反应和从头性高血压。
Epistemonikos ID: 663ba8457511690c1e6a5d485bb7e2ed223c9575
First added on: Jan 08, 2015
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use